Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have shown to prevent heart failure progression, although the mechanisms remain poorly understood. Here we evaluated the effect of empagliflozin (EMPA, SGLT2i) in cardiac remodeling after myocardial infarction, the interplay with diabetes status an...

Descripción completa

Detalles Bibliográficos
Autores principales: Asensio Lopez, Maria del Carmen, Lax, Antonio, Hernandez Vicente, Alvaro, Saura Guillen, Elena, Hernandez-Martinez, Antonio, Fernandez del Palacio, Maria Josefa, Bayes Genis, Andoni, Pascual Figal, Domingo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419540/
https://www.ncbi.nlm.nih.gov/pubmed/32782412
http://dx.doi.org/10.1038/s41598-020-70454-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419540/
https://www.ncbi.nlm.nih.gov/pubmed/32782412
http://dx.doi.org/10.1038/s41598-020-70454-8

Ejemplares similares